Evidence map›Paper›PMID 37719086›Full record

ArticleJournal of immunology research2023

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer.

Qianqian Wang, Chunxaing Feng, Yuchun Chen, Tianming Peng, Yong Li, Kunlin Wu, Xiaoyong Pu, Hanzhong Chen, Jiumin Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qianqian WangDepartment of Urology, School of Medicine, South China University of Technology, Guangzhou 510006, China.ORCID https://orcid.org/0000-0003-4137-7931
Chunxaing FengDepartment of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
Yuchun ChenDepartment of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.ORCID https://orcid.org/0009-0004-2656-3466
Tianming PengDepartment of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.ORCID https://orcid.org/0000-0002-5875-0491
Yong LiDepartment of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.ORCID https://orcid.org/0000-0002-4854-5523
Kunlin WuDepartment of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
Xiaoyong PuDepartment of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.ORCID https://orcid.org/0000-0002-9738-6733
Hanzhong ChenDepartment of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.ORCID https://orcid.org/0000-0003-0132-6494
Jiumin LiuDepartment of Urology, School of Medicine, South China University of Technology, Guangzhou 510006, China.ORCID https://orcid.org/0000-0002-2593-0285

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: CD47 has high levels of expression in malignant cancer cells, which binds to SIRP- Methods: The GEPIA database was utilized to compare the abundance of CD47 in malignant tissues with tissues that were normal. Furthermore, the function of CD47 in prostate carcinoma was assessed by CancerSEA. The association among CD47 and the tumor microenvironment was assessed utilizing the TISCH single cell data database. By using TIMER, the connection among CD47 and immunological invasion of prostate cancer was explored. Moreover, macrophages were cocultured with mouse prostate cancer cell RM-1 blocked by CD47 antibody to observe the changes in phagocytosis efficiency Results: Expression level of CD47 is upregulated in prostate carcinoma, and it is closely connected with prostate cancer's inadequate immune invasion. CD47 antibody blocking promotes macrophage phagocytosis of RM-1. Conclusion: Our research demonstrates a closely relationship among CD47 and the immunological microenvironment of prostate cancer, and blocking CD47 can promote macrophages to phagocytosis of prostate cancer cells. Therefore, CD47 may provide novel strategies for potential immunotherapy of prostate cancer.

Indexed as

CarcinomaProstatic NeoplasmsAnimalsAntibodiesCD47 AntigenHumansImmunotherapyMaleMiceTumor MicroenvironmentAntibodiesCD47 AntigenCD47 protein, human

Identifiers

PMID37719086
PMCPMC10505079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.